Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18 - Concepedia

Concepedia

Publication | Open Access

Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18

DOI Full Paper Access

178

Citations

15

References

2005

Year

Natasha B. Leighl, Luis Paz‐Ares, Jean-Yves Douillard, Christian Peschel, Andrew Arnold, A Depierre, Armando Santoro, Daniel Betticher, U. Gatzemeier, Jacek Jassem,

Journal of Clinical Oncology

Abstract

BMS-275291 added to chemotherapy increases toxicity and does not improve survival in advanced NSCLC.

References

	Year	Citations

Page 1